Bayer showcases product offerings and announces expansion of AI offerings in radiology

Bayer showcases product offerings and announces expansion of AI offerings in radiology

  • Showcase a spread of workflow options, subsequent technology CT know-how; Aiming to deal with right now’s ache factors in radiology

  • introduced collaboration agreements to broaden choices on Calantic’s new medical imaging platformTM Digital options throughout main illness areas

  • Presenting new scientific knowledge on an investigational distinction agent

Pittsburgh, November 23, 2022– (working wire) – As worldwide leaders in imaging collect for the 2022 Radiological Society of North America (RSNA) Annual Assembly, Bayer Radiology, a frontrunner in diagnostic imaging, will showcase its suite of merchandise and options aimed toward addressing right now’s most urgent points dealing with radiology. As well as, Bayer will current new scientific knowledge on the investigational distinction agent. The 2022 RSNA Championship will probably be held from November 27 to December 1 in Chicago.

Bayer’s focus areas in RSNA symbolize the corporate’s dedication to serving to tackle staffing shortages with options targeted on affected person productiveness and workflow effectivity to drive automation and standardization, investing in science for the good thing about sufferers and their physicians and harnessing the huge potential of information and synthetic intelligence.

Subsequent-generation tomography know-how and workflow options spotlight built-in choices that handle complexity and ship correct diagnostic info extra effectively.

Bayer’s introduction of Injector Administration software program* permits consistency and standardization by offering the flexibility to share widespread protocols via related injectors. *Not but commercially obtainable.

Bayer will showcase its subsequent technology CT know-how, the MEDRAD Centargo intravenous CT system (Centargo) in RSNA (Centargo Pending 510(okay) and never obtainable on the market within the US. The newest addition to the Bayer CT portfolio is designed to boost workflow effectivity with options Design works together with the Bayer household of merchandise to introduce revolutionary imaging array know-how and introduce new know-how within the areas of affected person preparation.

expanding AI affords on CalanticTM digital options
Bayer additionally pronounces collaboration agreements with utility builders Quantib, ClariPi, and EXINI Diagnostics to strategically broaden providing on its medical imaging platform CalanticTM digital options. The platform, which was launched not too long ago, gives entry to purposes, together with these enabled by synthetic intelligence, for medical imaging. With these new collaborations, Bayer is increasing the choices already obtainable for thoracic and neurology on the platform by together with instruments supposed to assist in breast and prostate imaging.

Introducing Calantech Utility Acceleration ProgramTM spark
As well as, Bayer not too long ago launched CalanticTM SPARK, a brand new accelerator program for medical imaging utility builders to drive innovation in radiology with AI. This system will initially give attention to North America and Europe and is ready to be expanded to different areas together with the Asia Pacific area. Bayer affords a focused program aimed toward accelerating market readiness for early stage initiatives and proposals, offering recommendation that features medical, regulatory, reimbursement and market entry experience. By leveraging the thriving rising ecosystem for AI in medical imaging, Calantic SPARK affords program contributors a possible path towards commercialization and distribution via Calantic Digital Options. Particulars about Calantic SPARK will probably be offered on the Bayer stand in addition to the AI ​​Showcase at RSNA.

company seminars

The position of a high-relaxing distinction agent in central nervous system imaging and MRA
Monday, November 28, 9:30 a.m. (CT)
Room: S102AB

From the idea of synthetic intelligence to authentication; The position of AI coordination platforms
Showcase Theatre
Monday, November 28, 1:00 p.m. (CT)
Room: S102AB

sparks of cooperation, How Bayer approaches the startup ecosystem.
Monday, November 28, 11:00 a.m. (CT)
Room: AI Theatre

Strategies and concerns in liver imaging.
Tuesday, November 29 at 10:30 a.m. (CT)
Digital Product Theater

Driving AI innovation to guage billable purposes
Wednesday, November 30, 3:00 p.m. (CT)
Innovation Theatre

Scientific presentation of a brand new, investigative molecular entity

Bayer will current the outcomes of early scientific trial knowledge on an investigational distinction agent. Gadoquatrane is a gadolinium-based distinction agent in Section II growth. The research investigated the pharmacokinetics together with the excretory pathways, and the security and tolerability of gadoquatrine in wholesome volunteers.

about Bayer
Bayer is a world group with core competencies within the life sciences areas of well being care and vitamin. Its services and products are designed to assist individuals and the planet thrive by supporting efforts to grasp the main challenges posed by a rising and growing older world inhabitants. Bayer is dedicated to driving sustainable growth and making a optimistic influence in its enterprise. On the identical time, the group goals to extend its incomes capability and create worth via innovation and progress. The Bayer model represents worldwide belief, reliability and high quality. Within the 2021 monetary yr, the group employs round 100,000 individuals and has a turnover of €44.1 billion. Analysis and growth expenditures earlier than particular objects amounted to €5.3 billion. For extra info, go to

Yow will discover extra info at
Comply with us on Fb:
Comply with us on Twitter: @employee

Ahead-looking statements
This launch might comprise forward-looking statements which might be primarily based on present assumptions and expectations set by Bayer’s administration. Many recognized and unknown dangers, uncertainties and different elements might trigger materials variations between precise future outcomes, monetary situation, growth or efficiency of the Firm and the estimates made herein. These elements embody these mentioned in Bayer’s public stories which might be obtainable on the Bayer web site The Firm assumes no obligation by any means to replace these forward-looking statements or to adapt them to future occasions or developments.

View supply model on


Media inquiries:
Jennifer Could, tel., 412-656-8192
Electronic mail: [email protected]

#Bayer #showcases #product #choices #pronounces #growth #choices #radiology

Leave a Reply

Your email address will not be published.